- Oral insulin would relieve pain and inconvenience, and drive patients to get treatment earlier, and possibly halt disease progression.
- The path to oral insulin taken by Oramed and Novo Nordisk is similar.
- Oramed's Phase IIa result were confirmed and praised by a participating CRO.
- If success making oral insulin in achieved, investors risk missing acquiring Oramed's shares at its current low price.
- Risks still abound for Oramed's success in later trials, especially for efficacy.